The companies did not disclose the financial terms of the settlement agreement. AbbVie shares rose 1.43 percent to $92 in after-hours trading. Iovance Reports Results from End-of-Phase 2 Meeting With FDA, To Sell Shares Iovance Biotherapeutics Inc (NASDAQ: IOVA ) said, following an end-of-Phase 2 meeting with the FDA regarding lead candidate lifileucel, the regulatory body acknowledged that a single-arm cohort as part of C-144-01 could be supportive of initial registration, and conduct of a randomized Phase 3 trial in the patient population being enrolled may not be feasible. Lifileucel is an autologous cell therapy being evaluated for malignant melanoma and other potential indications. The agency also granted RMAT designation for advanced melanoma, which vests advantages such as increased access to FDA during development, possibility of getting accelerated approval, and a rolling review of the BLA. Iovance said it expects BLA submission in the second-half of 2020.